Get the Stockscreener App
2.85
4.36%
-0.13
Exagen Inc stock is traded at $2.85, with a volume of 34,810.
It is down -4.36% in the last 24 hours and down -1.04% over the past month.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
See More
Previous Close:
$2.98
Open:
$3.06
24h Volume:
34,810
Relative Volume:
1.16
Market Cap:
$50.68M
Revenue:
$52.55M
Net Income/Loss:
$-23.69M
P/E Ratio:
-1.4109
EPS:
-2.02
Net Cash Flow:
$-15.29M
1W Performance:
-4.04%
1M Performance:
-1.04%
6M Performance:
+51.60%
1Y Performance:
+81.32%
1-Day Range:
$2.78
$3.08
1-Week Range:
$2.62
$3.084
52-Week Range:
$1.3003
$3.71
Exagen Inc Stock (XGN) Company Profile
Name
Exagen Inc
Sector
Industry
Phone
(760) 560-1501
Address
1261 LIBERTY WAY, VISTA, CA
Compare XGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| XGN | 2.87 | 50.68M | 52.55M | -23.69M | -15.29M | -2.02 |
| TMO | 500.25 | 192.46B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 229.65 | 165.90B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 126.30 | 36.48B | 6.50B | 1.41B | 1.42B | 3.82 |
| IDXX | 421.38 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
| IQV | 190.39 | 34.31B | 15.32B | 1.41B | 1.96B | 5.95 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Apr-15-21 | Initiated | Canaccord Genuity | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cowen | Outperform |
| Oct-14-19 | Initiated | William Blair | Outperform |
View All
Exagen Inc Stock (XGN) Latest News
What is William Blair's Forecast for Exagen FY2024 Earnings? - MarketBeat
Cantor Fitzgerald Raises Earnings Estimates for Exagen - MarketBeat
Cantor Fitzgerald Increases Earnings Estimates for Exagen - Defense World
Exagen Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
William Blair Reiterates “Outperform” Rating for Exagen (NASDAQ:XGN) - Defense World
Exagen unveils new biomarkers to enhance autoimmune testing - Investing.com
Exagen Inc. Completes Validation and Regulatory Submission - GlobeNewswire
Exagen Enhances AVISE CTD Platform with 7 New Biomarkers for Autoimmune Disease Detection | XGN Stock News - StockTitan
Exagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Exagen Inc. to Participate in Fourth Quarter Investor Conferences - The Manila Times
Exagen stock holds Sector Weight amid mixed 3Q24 results By Investing.com - Investing.com Australia
Exagen CEO to Present at Three Major Healthcare Investor Conferences | XGN Stock News - StockTitan
Exagen (NASDAQ:XGN) Receives Outperform Rating from William Blair - MarketBeat
Exagen Inc. (NASDAQ:XGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Ch - GuruFocus.com
Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... - Yahoo Finance
Exagen Inc. Reports Q3 2024 Financial Results - TipRanks
Exagen Inc. (XGN) Quarterly 10-Q Report - Quartzy
Exagen stock holds Sector Weight amid mixed 3Q24 results - Investing.com
Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates - MSN
Exagen Inc (XGN) Q3 2024 Earnings: Revenue Misses Estimates at $12.5M, Net Loss Narrows to $5.0M - GuruFocus.com
Exagen Inc. Reports Third Quarter 2024 Results - GlobeNewswire
Exagen Q3 Revenue Hits $12.5M Despite Setbacks; YTD Performance Shows 37% Loss Reduction | XGN Stock News - StockTitan
Exagen Inc (XGN) Q3 2024 Earnings Report Preview: What To Expect - GuruFocus.com
Exagen (XGN) to Release Earnings on Tuesday - Defense World
Exagen to Announce Third Quarter 2024 Results on November 12, 2024 - GlobeNewswire
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence - The Manila Times
Renaissance Technologies LLC Boosts Holdings in Exagen Inc. (NASDAQ:XGN) - Defense World
Exagen Insider Stock Sales Prove Timely As Market Valuation Descends To US$47m - Simply Wall St
Stonepine Capital Management LLC Has $653,000 Holdings in Exagen Inc. (NASDAQ:XGN) - Defense World
Exagen Inc. (NASDAQ:XGN) Shares Sold by Nantahala Capital Management LLC - Defense World
Exagen's SWOT analysis: diagnostic firm's stock poised for growth amid challenges - Investing.com
Exagen Inc. (NASDAQ:XGN) Short Interest Up 20.9% in September - MarketBeat
Octopus Energy acquires solar and storage company Exagen Group - Yahoo Finance
Octopus buys British solar and battery storage firm Exagen - Reuters
PARP Inhibitor Biomarkers Market Expected to Reach $1.75 Billion by 2031 - WhaTech
Autoimmune Disease Diagnostics Market 2024 Global Insights and Business Scenario 2031 - Newstrail
San Diego 2024 Top Tech Awards ceremony set for Sept. 26 at Snapdragon Stadium - CBS News 8
Autoimmune Disease Testing Market to Reach $12.1 Billion, Globally, by 2033 at 8.6% CAGR: Allied Market Research - PR Newswire UK
Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now - MSN
Shareholders in Exagen (NASDAQ:XGN) have lost 84%, as stock drops 12% this past week - Yahoo Finance
PARP Inhibitor Biomarkers Market to Surge with 8.8% CAGR by 2031 - WhaTech
Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified - Simply Wall St
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference - ForexTV.com
Exagen Inc. (NASDAQ:XGN) Short Interest Down 41.5% in August - MarketBeat
Short Interest in Exagen Inc. (NASDAQ:XGN) Decreases By 41.5% - Defense World
Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock - Yahoo Finance
Matthew G. Brown - Wilson Sonsini
Detailed Analysis of Personalized Medicine Market Exploring Future Growth Potential, New Developments, Comp... - WhaTech
XGN (Exagen) EBITDA : $-13.05 Mil (TTM As of Jun. 2024) - GuruFocus.com
XGN (Exagen) Debt-to-EBITDA : -3.02 (As of Jun. 2024) - GuruFocus.com
Exagen Inc Stock (XGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.78%
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):